First China-manufactured Trastuzumab Biosimilar HLX02 Global Phase III Trial Met Primary Endpoint in Breast Cancer
- Category: Antibodies
- Published on Monday, 25 November 2019 14:40
- Hits: 1351
SINGAPORE I November 22, 2019 I The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study to be reported at the ESMO Asia Congress 2019. (1)
“Trastuzumab is not widely accessible around the world due to its high cost. The entry of more affordable versions of trastuzumab such as HLX02 could open up treatment access,” said study first author Binghe Xu, Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
The anti-HER2 antibody trastuzumab given in combination with chemotherapy has significantly improved overall survival in patients with HER2-positive breast cancer and become the standard of care over the past decade. However, the cost can limit patient access to this treatment in regions with limited financial resources for healthcare. (2)
The development of biosimilars, which are medicinal products containing a similar version of the active substance of their biological originator or reference product and are derived from living organisms, (3) offers a way of improving access to cancer treatments by increasing treatment options and reducing cost. (4)
The new study randomised women with HER2-positive breast cancer to HLX02, a fully humanised anti-HER2 that was developed in China as a trastuzumab biosimilar, or to reference trastuzumab sourced from the European Union.
“Overall response rate at week 24 was similar for HLX02 and reference trastuzumab with no statistical difference observed between the two treatment groups,” reported Xu. The rates of adverse events and treatment emergent adverse events were similar for HLX02 and reference trastuzumab and there were no differences in safety profiles or immunogenicity.
“HLX02 is equally safe and effective as the reference trastuzumab and has been rigorously evaluated by regulatory authorities such as the European Medicines Agency (EMA), based on sound scientific principles,” said Xu. He added, “HLX02 has a clear potential to drive down spending on HER2+ cancer treatment,” although he said the price has not yet been agreed.
Commenting on the relevance of the new data, Rosa Giuliani, Consultant Medical Oncologist, Clatterbridge Cancer Centre, Liverpool, UK, said: “The development of biosimilars is important both for patients, by improving access to cancer drugs, and for health systems, allowing cost savings that can be re-invested in patient care and support the sustainability of healthcare systems.” She noted that other trastuzumab biosimilars have been approved in Europe so the potential approval of China-produced HLX02 would add a further option.
Giuliani warned: “Access to cancer medicines is a huge problem throughout the world, applying to relatively inexpensive medicines but even more to more expensive drugs such as monclonal antibodies. A survey carried out by ESMO in 2016 and the subsequent follow-up study showed that many patients in different countries, including Europe, have difficulty in accessing cancer medicines. What is even more astonishing is that this includes medicines listed in the World Health Organization’s (WHO) Essential Medicines List, such as trastuzumab. (5) It is not acceptable that medicines which have shown to have a major impact on patients survival are not given to patients in need. Biosimilars are safe and effective drugs which can finally allow those patients to receive an appropriate standard of care.”
Rebecca Dent, Head of Medical Oncology at the National Cancer Center Singapore, added: “The development of biosimilars means that more women will have access to potentially life-saving HER2-targeted therapies because of the cost-savings they provide. Development of biosimilars introduces competition and potentially lowers the price of drugs.”
Dent added, “As more biosimilar therapies are being developed there is also a need for vertical integration of the biomarkers that identify patients who will benefit.” For trastuzumab biosimilars this means ensuring access to HER2 status testing.
Reviewing the quality of the study design, Dent considered it important that the clinical programme with HLX02 was developed in consultation with the EMA and the China National Medical Products Administration (NMPA). The interim results of the study have been submitted to the NMPA and EMA to support approval of HLX02 in China and Europe.
The phase III study randomised 649 women with HER2+ recurrent or previously untreated metastatic breast cancer to HLX02 or EU-sourced trastuzumab (EU-TZB) (dose of 8mg/kg for both drugs) with docetaxel on day 1. Cycle 1 was followed by a dose of 6mg/kg in three-weekly cycles for up to 12 months. The women were recruited from 89 centres in China, the Philippines, Poland and Ukraine.
Result showed similar overall response rate at 24 weeks with HLX02 (71.0%) as with EU-TZB (71.4%, p=0.952). The risk difference in overall response rates between the two groups was -0.4% (95% confidence interval [CI] -7.4, 6.6), which was within the predefined margin (+13.5%).
All secondary endpoints, including overall response rates at weeks 6, 12 and 18, clinical benefit rate, disease control rate, duration of response, progression-free survival and overall survival at week 24 were similar for HLX02 and EU-TZB. The disease control rate was 83.0% in the HLX02 group and 84.3% in the reference trastuzumab group (p=0.646). The median progression-free survival with HLX02 was 11.7 months compared to 9.69 months with trastuzumab (p=0.079).
In each treatment group 98.8% of the patients reported at least one adverse event or treatment emergent adverse event and a similar number of adverse events were reported in the two treatment groups. There were no differences in safety profiles or immunogenicity between HLX02 and reference trastuzumab.
Notes to Editors
Official Congress Hashtag: #ESMOAsia19
- Abstract LBA6 ‘First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer’ will be presented will be presented during the Proffered paper session – Breast cancer, Saturday 23 November 2019, 09:00-10:30 SGT, Hall 405. Annals of Oncology, Volume 30, 2019 Supplement 9
- Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals 2014; 7: 943-953.
- ESMO Biosimilar Portal
- ESMO Understanding biosimilars for cancer patients.
- Cherny N, Sullivan R, Torode J et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Annals of Oncology 2016; 27: 1423-1442
LBA6 - First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
B. Xu1, Q. Zhang2, T. Sun3, W. Li4, Y. Teng5, X. Hu6, I. Bondarenko7, H. Adamchuk8, Y. Li9, B. Shan9, J. Cheng9, T. Peng9, X. Wang10, Y. Chen10, W. Jiang11, S. Liu11, X. Zhang9, E. Liu9, A. LUK9, Q. Wang9
1Internal Medicine, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, 2Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China, 3Internal Medicine, Liaoning Cancer Hospital and Institution, Shenyang, China, 4Internal Medicine, The First Bethune Hospital of Jilin University, Changchun, China, 5Internal Medicine, The First Hospital of China Medical University, Shengyang, China, 6Internal Medicine, Fudan University Shanghai Cancer Center, Shanghai, China, 7Internal Medicine, CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Department of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipo, Ukraine, 8Internal Medicine, 8CI Kryvyi Rih Oncological Dispensary of DRC, Dnipropetrovsk, Ukraine, 9Global Clinical and Medical Affairs, Shanghai Henlius Biotech, Inc., Shanghai, China, 10Global Regulatory Affairs, Shanghai Henlius Biotech, Inc., Shanghai, China, 11Executive Office, Shanghai Henlius Biotech, Inc., Shanghai, China
Background: HLX02, a fully-humanised anti-HER2 monoclonal antibody, was developed as trastuzumab (TZB) biosimilar to potentially increase treatment accessibility. The clinical program was developed in consultation with China National Medical Products Administration (NMPA) and European Medicines Agency (EMA) for global development. Previously, we reported clinical PK equivalence of HLX02 and TZBs at the ESMO-ASIA 2018 meeting. Here, we report the phase III study results.
Methods: We conducted a randomised, double-blind, parallel-controlled phase III study of HLX02 and EU-TZB at 89 centres in China, Philippines, Poland and Ukraine. Eligible adult women with HER2+ breast cancer were randomised to 8 mg/kg of either HLX02 or EU‑TZB with docetaxel on Day 1 Cycle 1 followed by a dose of 6 mg/kg in 3‑weekly cycles for up to 12 months. Primary endpoint was best overall response rate at Week 24 (ORRwk24). Secondary endpoints included ORR at weeks 6, 12, 18 and 24, clinical benefit rate (CBR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety profiles up to 12 months.
Results: Of the 649 patients being randomised (HLX02=324; EU‑TZB=325), the ORRwk24 (HLX02=71.0%; EU-TZB =71.4%; p=0.952) and risk difference in ORRs (-0.4%; 95% CI: -7.4, 6.6) between the two groups were within the pre-defined margin (±13.5%). All secondary efficacy analyses at Week 24 concluded the therapeutic equivalence. Both groups in all populations (overall, Asian vs. non-Asian, and Chinese vs. non-Chinese) had similar range values of CBR (HLX02: 78.6% - 86.8%; EU-TZB: 79.3% - 82.4%) and DCR (HLX02: 80.6% - 95.4%; EU-TZB: 86.9% - 89.2%). 641 (98.8%) reported at least 1 AE (HLX02 and EU-TZB were 98.8%). Similar incidences of AEs (HLX02: 6610; EU-TZB: 6788), TEAEs (HLX02: 6464; EU-TZB: 6638) and immunogenicity were reported at Week 24.
Conclusions: The use of HLX02 compared with EU‑TZB resulted in an equivalent ORR at Week 24. All secondary efficacy and safety analyses of HLX02 at Week 24 supported the conclusion of biosimilarity without clinical meaningful differences with EU‑TZB. This interim analysis has been submitted to NMPA and EMA to support marketing approval of HLX02 in China and Europe.
Clinical trial identification: NCT03084237; EudraCT: 2016-000206-10; Chinese Clinical Trial Register: 2015L01326
Legal entity responsible for the study: Shanghai Henlius Biotech, Inc.
Funding: Shanghai Henlius Biotech, Inc.
Disclosure: T. Sun: Research grant / Funding (institution): Shanghai Henlius Biotech, Inc. W. Li: Research grant / Funding (institution): Shanghai Henlius Biotech, Inc. Y. Teng: Research grant / Funding (institution): Shanghai Henlius Biotech, Inc. I. Bondarenko: Research grant / Funding (institution): Shanghai Henlius Biotech, Inc. H. Adamchuk: Research grant / Funding (institution): Shanghai Henlius Biotech, Inc. Y. Li: Full / Part-time employment: Shanghai Henlius Biotech, Inc. B. Shan: Full / Part-time employment: Shanghai Henlius Biotech, Inc. J. Cheng: Full / Part-time employment: Shanghai Henlius Biotech, Inc. T. Peng: Full / Part-time employment: Shanghai Henlius Biotech, Inc. X. Wang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. Y. Chen: Full / Part-time employment: Shanghai Henlius Biotech, Inc. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech, Inc. X. Zhang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. E. Liu: Full / Part-time employment: Shanghai Henlius Biotech, Inc. A. LUK: Full / Part-time employment: Shanghai Henlius Biotech, Inc. Q. Wang: Full / Part-time employment: Shanghai Henlius Biotech, Inc.
SOURCE: ESMO Asia